- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.40 Å
- Oligo State
- hetero-2-2-mer
- Ligands
- 1 x NAG- BMA- MAN: alpha-D-mannopyranose-(1-3)-beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 1 x NAG- NAG- BMA: beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 2 x AEY: 7-(benzyloxy)-1H-[1,2,3]triazolo[4,5-d]pyrimidin-5-amine(Non-covalent)
AEY.3: 9 residues within 4Å:- Chain A: Q.91, H.95, F.99
- Chain B: T.127, R.128, E.131, F.255, F.296
- Ligands: HEM.5
8 PLIP interactions:6 interactions with chain B, 2 interactions with chain A- Hydrophobic interactions: B:R.128, B:F.255, B:F.255, A:F.99
- Hydrogen bonds: B:R.128, B:E.131, A:Q.91
- Water bridges: B:R.222
AEY.21: 9 residues within 4Å:- Chain C: Q.91, H.95, F.99
- Chain D: T.127, R.128, E.131, F.255, F.296
- Ligands: HEM.14
7 PLIP interactions:5 interactions with chain D, 2 interactions with chain C- Hydrophobic interactions: D:R.128, D:F.255, D:F.255
- Hydrogen bonds: D:R.128, D:E.131, C:Q.91
- Water bridges: C:T.100
- 4 x CL: CHLORIDE ION(Non-functional Binders)
CL.4: 5 residues within 4Å:- Chain A: R.31, W.32
- Chain B: N.215, V.216, W.325
Ligand excluded by PLIPCL.13: 3 residues within 4Å:- Chain B: N.89, Q.90, F.102
Ligand excluded by PLIPCL.15: 6 residues within 4Å:- Chain C: V.30, R.31, W.32
- Chain D: N.215, V.216, W.325
Ligand excluded by PLIPCL.22: 3 residues within 4Å:- Chain D: N.89, Q.90, F.102
Ligand excluded by PLIP- 2 x HEM: PROTOPORPHYRIN IX CONTAINING FE(Covalent)
HEM.5: 22 residues within 4Å:- Chain A: M.87, G.90, Q.91, D.94, D.98, F.99, T.100
- Chain B: R.128, E.131, M.132, T.218, F.221, R.222, G.224, H.225, I.228, F.254, L.295, F.296, L.306, R.313
- Ligands: AEY.3
17 PLIP interactions:14 interactions with chain B, 3 interactions with chain A,- Hydrophobic interactions: B:E.131, B:M.132, B:F.221, B:R.222, B:I.228, B:F.254, B:L.295, B:F.296, B:L.306, B:L.306, A:Q.91, A:Q.91
- Salt bridges: B:R.128, B:R.222, B:R.313
- Metal complexes: B:H.225
- Hydrogen bonds: A:T.100
HEM.14: 22 residues within 4Å:- Chain C: M.87, G.90, Q.91, D.94, D.98, F.99, T.100
- Chain D: R.128, E.131, M.132, Y.185, T.218, F.221, R.222, G.224, H.225, I.228, F.254, F.296, L.306, R.313
- Ligands: AEY.21
19 PLIP interactions:14 interactions with chain D, 5 interactions with chain C,- Hydrophobic interactions: D:E.131, D:M.132, D:R.222, D:I.228, D:F.254, D:F.296, D:L.306, D:L.306, C:Q.91, C:Q.91
- Water bridges: D:T.218, D:R.222
- Salt bridges: D:R.128, D:R.222, D:R.313
- Metal complexes: D:H.225
- Hydrogen bonds: C:D.98, C:T.100, C:T.100
- 2 x CA: CALCIUM ION(Non-covalent)
CA.6: 5 residues within 4Å:- Chain A: D.96
- Chain B: T.57, F.59, D.61, S.63
5 PLIP interactions:4 interactions with chain B, 1 interactions with chain A- Metal complexes: B:T.57, B:F.59, B:D.61, B:S.63, A:D.96
CA.16: 5 residues within 4Å:- Chain C: D.96
- Chain D: T.57, F.59, D.61, S.63
5 PLIP interactions:4 interactions with chain D, 1 interactions with chain C- Metal complexes: D:T.57, D:F.59, D:D.61, D:S.63, C:D.96
- 5 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG.7: 5 residues within 4Å:- Chain B: N.206, V.209
- Chain D: R.327
- Ligands: NAG-BMA-MAN.1, FUC.8
2 PLIP interactions:1 interactions with chain D, 1 interactions with chain B- Hydrogen bonds: D:R.327
- Water bridges: B:N.206
NAG.9: 6 residues within 4Å:- Chain B: N.78, N.81, L.85, A.87, V.88, Q.90
6 PLIP interactions:6 interactions with chain B- Hydrophobic interactions: B:A.87
- Hydrogen bonds: B:N.78, B:N.81, B:V.88, B:Q.90, B:Q.90
NAG.10: 5 residues within 4Å:- Chain B: N.114, S.116, A.117, W.258, L.262
2 PLIP interactions:2 interactions with chain B- Hydrogen bonds: B:N.114, B:N.114
NAG.19: 6 residues within 4Å:- Chain D: N.78, N.81, L.85, A.87, V.88, Q.90
7 PLIP interactions:7 interactions with chain D- Hydrophobic interactions: D:A.87
- Hydrogen bonds: D:N.81, D:V.88, D:Q.90, D:Q.90
- Water bridges: D:N.78, D:N.78
NAG.20: 5 residues within 4Å:- Chain D: N.114, S.116, A.117, W.258, L.262
No protein-ligand interaction detected (PLIP)- 2 x FUC: alpha-L-fucopyranose(Non-covalent)
FUC.8: 4 residues within 4Å:- Chain B: V.209, R.393
- Ligands: NAG.7, MAN.12
3 PLIP interactions:3 interactions with chain B- Hydrophobic interactions: B:V.209, B:R.393
- Water bridges: B:K.394
FUC.18: 4 residues within 4Å:- Chain D: R.393
- Ligands: NAG-NAG-BMA.2, NAG-NAG-BMA.2, MAN.17
2 PLIP interactions:2 interactions with chain D- Hydrophobic interactions: D:R.393
- Water bridges: D:R.393
- 3 x MAN: alpha-D-mannopyranose(Non-covalent)
MAN.11: 2 residues within 4Å:- Chain B: K.197
- Ligands: NAG-NAG-BMA.2
1 PLIP interactions:1 interactions with chain B- Hydrogen bonds: B:K.197
MAN.12: 5 residues within 4Å:- Chain A: W.32
- Chain B: F.328, K.394
- Ligands: NAG-NAG-BMA.2, FUC.8
3 PLIP interactions:2 interactions with chain B, 1 interactions with chain A- Hydrogen bonds: B:K.394, A:W.32
- Water bridges: B:K.394
MAN.17: 5 residues within 4Å:- Chain C: W.32
- Chain D: F.328, K.394
- Ligands: NAG-BMA-MAN.1, FUC.18
2 PLIP interactions:2 interactions with chain D- Hydrogen bonds: D:K.394
- Water bridges: D:K.394
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Duclos, F. et al., Triazolopyrimidines identified as reversible myeloperoxidase inhibitors. Medchemcomm (2017)
- Release Date
- 2018-04-18
- Peptides
- Myeloperoxidase: AC
Myeloperoxidase: BD - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AC
DB
BD
E
- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.40 Å
- Oligo State
- hetero-2-2-mer
- Ligands
- 1 x NAG- BMA- MAN: alpha-D-mannopyranose-(1-3)-beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 1 x NAG- NAG- BMA: beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 2 x AEY: 7-(benzyloxy)-1H-[1,2,3]triazolo[4,5-d]pyrimidin-5-amine(Non-covalent)
- 4 x CL: CHLORIDE ION(Non-functional Binders)
- 2 x HEM: PROTOPORPHYRIN IX CONTAINING FE(Covalent)
- 2 x CA: CALCIUM ION(Non-covalent)
- 5 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 2 x FUC: alpha-L-fucopyranose(Non-covalent)
- 3 x MAN: alpha-D-mannopyranose(Non-covalent)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Duclos, F. et al., Triazolopyrimidines identified as reversible myeloperoxidase inhibitors. Medchemcomm (2017)
- Release Date
- 2018-04-18
- Peptides
- Myeloperoxidase: AC
Myeloperoxidase: BD - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AC
DB
BD
E